|
Schirdewan博士的引述的參考文獻: ) Z- }- w/ ^; z+ }5 o, S
}5 ?" F; D+ c3 _& t6 I7 n% X) F
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. 6 R" P& m) c+ p+ x9 e
0 Y E4 A* W% p0 s0 `% o! b. y5 JDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 9 w, a- z# \$ R$ q/ K
, g' j+ G) h8 n( o9 X Q' HRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. / d- a( H% C; X2 S
/ A- ~ M3 O& f% n/ f
關於BIOTRONIK SE & Co. KG5 M4 J+ q# |0 l! c% Y, ]$ \$ w
" o" K) X% g tBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|